Homologous recombination deficiency (HRD) is a well-described phenotype of some prostate cancers; however, current biomarkers for HRD are imperfect and rely on detection of single gene alterations in ...

Impact of Genomic Alterations on Efficacy of Trastuzumab Deruxtecan Against Human Epidermal Growth Factor Receptor-2–Positive Advanced Gastric Cancer This was a prospective, cross-sectional, ...

Please provide your email address to receive an email when new articles are posted on . Adding niraparib to abiraterone acetate and prednisone lowered risk for cancer growth by 37% among certain ...

A recent study, undertaken by researchers at the Tokyo Metropolitan University and the Tokyo Metropolitan Institute of Medical Science (both Japan), unravels key steps in the process of homologous ...

Therapeutic landscape of Rad51 in cancer treatment. Key elements include (1) DNA damage sources (PARPi, chemo/radiotherapy);(2) repair pathways (Rad51‐mediated HR); (3) intervention strategies (Rad51 ...

Identifying BRCAness in tumors, even in the absence of BRCA mutations, broadens the reach of targeted therapies, supporting more individualized and effective cancer treatment approaches. BRCAness ...

The FDA approved updated labeling for Talzenna plus Xtandi for HRR gene-mutated metastatic castration-resistant prostate cancer, based on the TALAPRO-2 trial results. The TALAPRO-2 trial showed a ...